SUPN Quote, Financials, Valuation and Earnings

Collegium Pharmaceutical has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 1.36%. Supernus Pharmaceuticals's return on equity of 6.24% beat Collegium Pharmaceutical's return on equity of 19.31%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 20.65%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 40.12%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.710, which suggesting that the stock is 28.985% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.635, suggesting its less volatile than the S&P 500 by 36.534%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Supernus Pharmaceuticals's net income of -$11.8M is lower than Collegium Pharmaceutical's net income of $2.4M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.12x while Collegium Pharmaceutical's PE ratio is 24.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.71x versus 1.71x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.68%. Supernus Pharmaceuticals's return on equity of 6.24% beat Eli Lilly and's return on equity of 78.25%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 20.65%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 20.31%. Given that Supernus Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Supernus Pharmaceuticals is more attractive than Eli Lilly and.

Supernus Pharmaceuticals has a beta of 0.710, which suggesting that the stock is 28.985% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.12x while Eli Lilly and's PE ratio is 64.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.71x versus 14.58x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.63%. Supernus Pharmaceuticals's return on equity of 6.24% beat Pfizer's return on equity of 8.72%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 20.65%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.83%. Given that Pfizer has higher upside potential than Supernus Pharmaceuticals, analysts believe Pfizer is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.710, which suggesting that the stock is 28.985% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.08% to investors and pays a quarterly dividend of $0.43 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Pfizer's net income of $3B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.12x while Pfizer's PE ratio is 17.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.71x versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 28.42%. Supernus Pharmaceuticals's return on equity of 6.24% beat Zoetis's return on equity of 51.03%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 20.65%. On the other hand Zoetis has an analysts' consensus of $195.37 which suggests that it could grow by 18.85%. Given that Supernus Pharmaceuticals has higher upside potential than Zoetis, analysts believe Supernus Pharmaceuticals is more attractive than Zoetis.

Supernus Pharmaceuticals has a beta of 0.710, which suggesting that the stock is 28.985% less volatile than S&P 500. In comparison Zoetis has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.913%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.13% to investors and pays a quarterly dividend of $0.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Zoetis quarterly revenues of $2.2B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Zoetis's net income of $631M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 29.12x while Zoetis's PE ratio is 29.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.71x versus 8.00x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.